NDA 208945 · Lnhc
Xepi
Ozenoxacin · Topical
NovelDiscontinuedLast checked: Nov 19, 2026Latest source record: Feb 4, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Dec 11, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- XEPI · OZENOXACIN 1% · CREAM, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ozenoxacin" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoPivotal-lookingCompleted
Ferrer Internacional S.A.Industry
NCT01397461 · 465 participants · Start Mar 2012 · Primary completion Dec 2012
Drug: ozenoxacin placebo; retapamulin 1% ointment and 1 more · For: Impetigo
Sites: Augsburg, Germany; Cologne, Germany; Dresden, Germany · 19 sites in all
- Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoPivotal-lookingCompleted
Ferrer Internacional S.A.Industry
NCT02090764 · 412 participants · Start Jun 2014 · Primary completion May 2015
Drug: Ozenoxacin; Placebo · For: Impetigo
Sites: Rio Grande, Puerto Rico
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents.
Torrelo A, Grimalt R, Masramon X, et al. · Dermatology 2020 · Clinical Trial, Phase I, Clinical Trial, Phase III
- A comparative review of current topical antibiotics for impetigo.
Galindo E, Hebert AA · Expert Opin Drug Saf 2021 · Comparative Study, Systematic Review
- Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers.
Gropper S, Albareda N, Santos B, et al. · Future Microbiol 2014 · Clinical Trial, Phase I, Randomized Controlled Trial
- Ozenoxacin Cream, 1% - Topical Treatment of Impetigo.
Gupta AK, Versteeg SG, Abramovits W · Skinmed 2017 · Randomized Controlled Trial
- Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
Gropper S, Albareda N, Chelius K, et al. · Future Microbiol 2014 · Multicenter Study, Randomized Controlled Trial
- Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.
Rosen T, Albareda N, Rosenberg N, et al. · JAMA Dermatol 2018 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Lnhc
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.